PierianDx
Velsera to Integrate Arima Genomics Gene Fusion Test in Pierian Clinical Platform
Pierian, now a part of Velsera, is integrating Arima's gene fusion sequencing technology into its NGS analysis, interpretation, and reporting hub.
In Brief This Week: Pierian, PerkinElmer, Decode Health, Quest, Nucleix, More
News items for the week of Oct. 17, 2022.
PierianDx Closes Equity Financing, Loan Facility for up to $47.5M
OrbiMed was the lead investor in the new financing, which is expected to drive PierianDx's commercial expansion. The firm raised $27 million in 2019.
Illumina, PierianDx Expand Partnership on Cancer Panel Test Reporting
The deal builds on a non-exclusive partnership signed in January 2019 and PierianDx will now support three more Illumina cancer sequencing assays.
PierianDx, Pillar Biosciences Partner to Streamline NGS Cancer Analysis
PierianDx will integrate its cancer profiling assays with Pillar Biosciences' PiVAT bioinformatics pipeline on a GPDR-compliant platform.
Oct 28, 2019